Closing Thoughts on the Future Landscape

The panel offers closing reflections on the future of neuroendocrine tumor treatment. Faculty highlight how dramatically the landscape has evolved over the past decade, with expanding therapeutic options, new diagnostic approaches, and multiple ongoing trials exploring targeted therapies and next-generation radioligand approaches. Speakers emphasize that this is a disease of prolonged survival, making delay of progression and preservation of quality of life as important as tumor shrinkage. They commend inclusive trial designs that incorporate lung and other historically excluded populations and call for continued attention to these underserved groups. Faculty acknowledge that longer patient survival creates ongoing demand for additional options and urge exploration of targets beyond the established somatostatin, VEGF, and mTOR pathways. The discussion closes with emphasis on involving patients and caregivers, addressing disease burden, financial hardship, and quality of life, and expressing optimism that care will continue to advance meaningfully over the coming years.